CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus